High-Intensity Statin vs. Low-Density Lipoprotein Cholesterol Target for Patients Undergoing Percutaneous Coronary Intervention: Insights From a Territory-Wide Cohort Study in Hong Kong

Andrew Kei-Yan Ng*, Pauline Yeung Ng2,3, April Ip3 and Chung-Wah Siu4

1 Cardiac Medical Unit, Grantham Hospital, Wong Chuk Hang, Hong Kong, SAR China, 2 Department of Adult Intensive Care, Queen Mary Hospital, Hong Kong, SAR China, 3 Division of Respiratory and Critical Care Medicine, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR China, 4 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, SAR China

Background: Different guidelines recommend different approaches to lipid management in patients with atherosclerotic cardiovascular disease. We aim to determine the best strategy for lipid management in Asian patients undergoing percutaneous coronary intervention (PCI).

Method: This was a retrospective cohort study conducted in patients who underwent first-ever PCI from 14 hospitals in Hong Kong. All participants either achieved low-density lipoprotein cholesterol (LDL-C) target of <55 mg/dl with ≥50% reduction from baseline (group 1), or received high-intensity statin (group 2), or both (group 3) within 1 yr after PCI. The primary endpoint was a composite outcome of all-cause mortality, myocardial infarction, stroke, and any unplanned coronary revascularization between 1 and 5 yr after PCI.

Results: A total of 8,650 patients were analyzed with a median follow-up period of 4.2 yr. After the adjustment of baseline characteristics, complexity of PCI and medications prescribed and the risks of the primary outcome were significantly lower in group 2 (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.74–0.93, P = 0.003) and group 3 (HR, 0.75; 95% CI, 0.62–0.90; P = 0.002). The primary outcome occurred at similar rates between group 2 and group 3.

Conclusions: Use of high intensity statin, with or without the attainment of guidelines recommended LDL-C target, was associated with a lower adjusted risk of MACE at 5 yr, compared with patients who attained LDL-C target without high intensity statin.

Keywords: percutaneous coronary intervention, dyslipidemia, statin, low density lipoprotein cholesterol, major adverse cardiac events, all-cause mortality, myocardial infarction, stroke
BACKGROUND
Deposition of low-density lipoprotein cholesterol (LDL-C) within the arterial wall is a key initiating and propagating event in atherogenesis (1). Numerous randomized controlled trials (RCT) have established the pivotal role of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) in cardiovascular risk reduction for patients with established coronary artery disease (2, 3). However, there are different approaches in its clinical application. The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline recommended high intensity statin without specifying LDL-C targets for patients with established cardiovascular disease (4). In the 2018 revision, the ACC/AHA conjoined with other American societies continued the class I recommendation for routine high-intensity statins, with options of adjunctive lipid-lowering therapy in selected subgroups (5). In contrast, the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guideline recommended an LDL-C target of <55 mg/dl (<1.4 mmol/L) and a 50% LDL-C reduction from baseline for those with established cardiovascular disease which could be achieved by maximally tolerated statin and other lipid-lowering therapies (6).

Due to genetic polymorphism, the plasma levels of statin and its metabolites are generally doubled in Asians as compared with Caucasians (7, 8). Several studies have observed no significant outcome difference with high-intensity statins as compared with moderate intensity statins in Asian patients, (9–12) raising questions whether routine high-intensity statins are needed (13). However, one study showed benefits of high-intensity statins in Asians who attained a less contemporary LDL-C target of <70 mg/dl (<1.8 mmol/L) (14). There were no data comparing the effects of the ACC/AHA vs. ESC/EAS guidelines, especially for Asians. We aimed to determine the best approach to lipid management for Asian patients after percutaneous coronary intervention (PCI).

METHODS
Study Population and Design
Adult patients (18 yr of age or older) who underwent first-ever PCI between January 1, 2004, and December 31, 2017, at any of the 14 public hospitals in Hong Kong and entered the territory-wide PCI Registry were reviewed. Patient characteristics, exposures, and outcomes were retrieved from the Clinical Data and Analysis Reporting System (CDARS). The study was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority. The requirement for written informed consent was waived due to the retrospective nature of the study.

We included all patients who survived for at least 365 days after PCI. Patients with outcome events within 365 days were excluded to avoid reverse causality. Patients were excluded if they did not fulfill either the intensity criteria or target criteria as specified below.

Definitions of Exposure and Outcome Variables
The target criteria were fulfilled if LDL-C was reduced to <55 mg/dl for at least one measurement between 0 and 365 days after PCI, together with ≥50% reduction from baseline if the patient was not previously on statins. The intensity criteria were fulfilled if the patients were prescribed high-intensity statins at any time between 0 and 365 days after PCI. High intensity statin was defined as atorvastatin ≥40mg per day, rosuvastatin ≥20 mg per day, or simvastatin ≥80 mg per day, in accordance with ACC/AHA guideline (remarks: simvastatin was not considered high intensity statin after 2011) (4, 5). Patients were grouped according to the lipid management strategy into three groups. Group 1 included patients fulfilling the target criteria only, group 2 included those fulfilling the intensity criteria only, and group 3 included those fulfilling both target and intensity criteria.

The primary endpoint was a major adverse cardiac event (MACE), defined as a composite outcome of all-cause mortality, non-fatal myocardial infarction, stroke, or any unplanned coronary revascularization, in a time-to-first-event analysis up to 5 yr after PCI. The secondary endpoints were individual components of the primary endpoint, and a composite outcome of all-cause mortality, non-fatal myocardial infarction (MI), and stroke. Detailed definitions are shown in the Supplementary Appendix.

Statistical Analysis
All analyses were performed with prespecified endpoints and statistical methods. Unadjusted analyses were performed using Chi-square tests for categorical variables and ANOVA tests for continuous variables. Pair-wise comparisons between the three exposure groups were performed for each endpoint. Cox regression analysis was performed to evaluate the independent relationship between lipid management strategy and clinical outcomes, adjusting for potential confounders selected a priori based on published data and biological plausibility. Variables adjusted in the Cox model were sex, age, tobacco use, diabetes mellitus, hypertension, dyslipidemia, cerebrovascular disease, peripheral vascular disease, chronic obstructive pulmonary disease, previous myocardial infarction, previous coronary artery bypass surgery, history of heart failure, atrial fibrillation or flutter, baseline anemia (last known hemoglobin before PCI <13 g/dl for men, or <12 g/dl for women), renal insufficiency (estimated glomerular filtration rate [eGFR] <60 ml/min/m²), indication for PCI (stable CAD, unstable angina, nonST elevation myocardial infarction [NSTEMI], and ST elevation myocardial infarction [STEMI]), number of coronary arteries affected, angiographic success, aspirin on discharge, P2Y12 inhibitors on discharge, beta-blocker on discharge, angiotensin blockade on discharge, and PCI period (before and after 2013ACC/AHA guideline) (4). The comorbidities were recorded as a part of mandatory input for the registry. The laboratory results, medication prescriptions, and outcomes were extracted from the CDARS.
Sensitivity Analyses
We examined a more stringent criteria, such that only patients who fulfilled criteria measured at both periods of 0–180 days and 181–365 days after PCI were considered as criteria fulfillment, and repeated the analysis examining the outcomes occurring between 365 days and 5 yr. Next, we assumed that all our patients belonged to the “very high risk” subgroup according to the 2018 ACC/AHA guidelines, (5) repeated the primary analysis after excluding those who did not achieve 50% reduction in LDL-C (if newly started on statin after PCI), and did not achieve an LDL-C of <70 mg/dl (<1.8 mmol/L) in group 2. In addition, we constructed a propensity score for the likelihood of fulfillment of either target criteria (i.e., group 1) or intensity criteria (i.e., group 2) using logistic regression with the variables in the primary regression model. Matched pairs were generated by 1:1 propensity-score-matching using a caliper of 0.05. Outcomes between the matched pairs were compared.

The complete case method was adopted to address missing data in the primary statistical analysis. To test the robustness of our results, the regression analysis was repeated with the
TABLE 1 | Baseline characteristics of patients.

| Characteristics | Group 1 (Target criteria only) | Group 2 (Intensity criteria only) | Group 3 (Both criteria) | P value |
|-----------------|-------------------------------|----------------------------------|-------------------------|---------|
| N               | 3,832                         | 3,512                            | 1,306                   |         |
| Female          | 924 (24.1%)                   | 680 (19.4%)                      | 225 (17.2%)             | <0.001  |
| Age, mean (SD)  | 66.5 (11.4)                   | 60.8 (10.8)                      | 62.7 (11.3)             | <0.001  |
| Chinese         | 3,648 (95.2%)                 | 3,234 (92.1%)                    | 1,230 (94.2%)           | <0.001  |
| Tobacco use     | 1,402/3,569 (39.3%)           | 1,704/3,356 (50.8%)              | 570/1,229 (46.4%)       | <0.001  |
| Diabetes mellitus| 1,753 (45.7%)                | 938 (26.7%)                      | 458 (35.1%)             | <0.001  |
| Hypertension    | 2,687 (70.1%)                 | 1,864 (53.1%)                    | 784 (60.0%)             | <0.001  |
| Cerebrovascular disease | 395 (10.3%)     | 221 (6.3%)                       | 93 (7.1%)               | <0.001  |
| Peripheral vascular disease | 56/3,819 (1.5%) | 33/3,502 (0.9%)                  | 11/1,300 (0.8%)         | 0.058   |
| Chronic obstructive pulmonary disease | 81 (2.1%)            | 44 (1.3%)                        | 26 (2.0%)               | 0.015   |
| Previous myocardial infarction | 498 (13.0%) | 329 (9.4%)                       | 92 (7.0%)               | <0.001  |
| Previous CABG   | 82 (2.1%)                     | 76 (2.2%)                        | 26 (2.0%)               | 0.93    |
| Congestive heart failure | 324 (8.5%)         | 151 (4.3%)                       | 52 (4.0%)               | <0.001  |
| Atrial fibrillation or flutter | 250 (6.5%)     | 84 (2.4%)                        | 39 (3.0%)               | <0.001  |
| eGFR < 60 ml/min/m² | 875 (22.8%)        | 384 (10.9%)                      | 194 (14.9%)             | <0.001  |
| Anemia*         | 1,363 (35.6%)                 | 881 (25.1%)                      | 369 (28.3%)             | <0.001  |
| PCI indication  |                              |                                  |                         | <0.001  |
| Stable CAD      | 849/3,824 (22.2%)             | 641/3,511 (18.3%)                | 219 (16.8%)             |         |
| Unstable angina | 874/3,824 (22.9%)             | 709/3,511 (20.2%)                | 209 (16.0%)             |         |
| NSTEMI          | 1,642/3,824 (42.9%)           | 1,558/3,511 (44.4%)              | 579 (44.3%)             |         |
| STEMI           | 459/3,824 (12.0%)             | 603/3,511 (17.2%)                | 299 (22.9%)             |         |
| Number of arteries involved |              |                                  |                         | <0.001  |
| One vessel disease | 1,828/3,808 (48.0%)          | 1,460/3,459 (42.2%)              | 576 (46.7%)             |         |
| Two vessel disease | 1,235/3,808 (32.4%)          | 1,183/3,459 (34.2%)              | 439 (34.1%)             |         |
| Three vessel disease | 745/3,808 (19.6%)            | 816/3,459 (23.6%)                | 272 (21.1%)             |         |
| Angiographic success | 3,741/3,819 (98.0%)        | 3,442/3,511 (98.0%)              | 1,275/1,306 (97.6%)     | 0.67    |
| Aspirin on discharge | 3,731 (97.4%)             | 3,424 (97.5%)                    | 1,279 (97.9%)           | 0.52    |
| P2Y12 inhibitor on discharge | 3,790 (98.9%) | 3,487 (99.3%)                    | 1,301 (99.6%)           | 0.030   |
| Beta-blocker on discharge | 2,977 (77.7%) | 2,602 (74.1%)                    | 1,006 (77.0%)           | 0.001   |
| Angiotensin blockade on discharge | 2,119 (55.3%) | 1,603 (45.6%)                    | 609 (46.6%)             | <0.001  |
| PCI done in 2013 or later | 2,401 (62.7%) | 2,870 (81.7%)                    | 1,199 (91.8%)           | <0.001  |

SD, standard deviation; CABG, coronary artery bypass surgery; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; CAD, coronary artery disease.

*Anemia: Hemoglobin <13g/dl for men, <12g/dl for women.

Entire cohort using the technique of multiple imputations by chained equations.

Exploratory Analyses

We studied the effect modifications on the relationship between lipid management strategy (group 2 vs. group 1) and primary outcome by introducing interaction terms to the Cox regression model. These included sex, age >65, diabetes mellitus, eGFR <60 ml/min/m², and acute coronary syndrome.

Data management and statistical analyses were performed in Stata software, version 16 (StataCorp LP). For each endpoint, the Bonferroni–Holm method was used to control for multiple comparisons to maintain a family-wise type I error rate of 0.05 (i.e., statistical significance achieved if P-value < 0.0167 for the lowest P-value; < 0.025 for the second-lowest P-value; < 0.05 for the third-lowest P-value) (15).

RESULTS

Patients and Characteristics

Between January 2004 and December 2017, a total of 36,346 patients were considered for inclusion, and 27,696 (76.2%) were excluded due to any of the following exclusion criteria: age younger than 18 yr, MACE occurred within 365 days after PCI, or no available lipid profile within 365 days after PCI, or fulfilled neither target nor intensity criteria. Of the remaining 8,650 patients analyzed, a total of 611 (7.1%) were excluded from the complete case analysis due to missing values in any of the variables used in the Cox regression model (Figure 1). The mean age was 63.6 ± 11.5. The cohort consisted of 1,829 (21.1%) female patients and 8,112 (93.8%) were Chinese. A total of 3,832, 3,512, and 1,306 patients were included in group 1, group 2, and group 3 respectively. Table 1 shows the baseline and characteristics of the study population. Patients in group 1 were older, more frequently
had diabetes, hypertension, previous myocardial infarction, heart failure, atrial fibrillation or flutter, chronic kidney disease, and anemia. Patients in group 2 and 3 more frequently had PCI done after 2013. Table 2 shows the lipid profile and lipid-lowering medications of the study population. The mean LDL-C at PCI and at one yr, and also the lowest LDL-C within the first yr was higher in group 2. The absolute reduction in LDL-C at one yr was higher in group 2 and group 3.

### Primary Outcome

After a median follow-up of 4.2 yr, the primary outcome of MACE has developed in 811 (21.2%) patients in group 1 in 448 (12.8%) in group 2, and in 160 (12.3%) in group 3 (Table 3 and Figure 2). In adjusted analysis with covariates listed in the Method section, the risks of MACE at 5 yr were significantly lower in group 2 (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.72–0.93; \( P = 0.003 \)) and group 3 (HR, 0.75; 95% CI, 0.62–0.90; \( P = 0.002 \)) (Table 4). The primary outcome occurred at similar rates between group 2 and group 3.

### Secondary Outcomes

Patients in group 2 had a lower risk of all-cause mortality compared with group 1 (HR, 0.77; 95% CI, 0.62–0.95; \( P = 0.015 \)). The composite endpoint of all-cause mortality, MI, and stroke was lower in group 2 (HR, 0.82; 95% CI, 0.71–0.95; \( P = 0.010 \)) and group 3 (HR, 0.78; 95% CI, 0.64–0.96; \( P = 0.020 \)). Other secondary outcomes were not significantly different across pairwise comparisons using the Bonferroni–Holm method to control for multiple comparison. Detailed results are shown in Table 4.

### Sensitivity Analyses

After reclassification of patients using more stringent criteria, there were 1,816 patients in group 1, 3,071 patients in group 2, and 538 patients in group 3. Patients in group 2 had a lower risk
FIGURE 2 | Unadjusted estimated probabilities of major adverse cardiovascular events stratified by lipid management strategy. Group 1 (target criteria only) had a higher risk of MACE compared with group 2 (intensity criteria only) and group 3 (both criteria).

TABLE 4 | Adjusted hazard ratios of primary and secondary outcomes.

| Outcomes                                | Group 1 (Target criteria only) | Group 2 (Intensity criteria only) | Group 3 (Both criteria) |
|-----------------------------------------|--------------------------------|----------------------------------|-------------------------|
|                                        | Hazard Ratio (95% CI)          | P Value                          | Hazard Ratio (95% CI)   | P Value |
| Primary                                 |                                |                                  |                         |         |
| Major adverse cardiovascular events     | Reference 0.82 (0.72–0.93)     | 0.003*                           | 0.75 (0.62–0.90)        | 0.002*  |
|                                         | Reference                      |                                  | 0.92 (0.76–1.11)        |         |
| Secondary                               |                                |                                  |                         |         |
| All-cause mortality                     | Reference 0.77 (0.62–0.95)     | 0.015*                           | 0.77 (0.58–1.02)        | 0.38    |
|                                         | Reference                      |                                  | 1.00 (0.73–1.37)        |         |
| Myocardial infarction                   | Reference 0.87 (0.70–1.09)     | 0.23                             | 0.82 (0.60–1.13)        | 0.99    |
|                                         | Reference                      |                                  | 0.94 (0.68–1.30)        |         |
| Stroke                                  | Reference 0.90 (0.67–1.20)     | 0.46                             | 0.99 (0.67–1.48)        | 0.37    |
|                                         | Reference                      |                                  | 1.11 (0.74–1.66)        |         |
| Unplanned revascularization             | Reference 0.87 (0.70–1.09)     | 0.22                             | 0.75 (0.54–1.04)        | 0.22    |
|                                         | Reference                      |                                  | 0.86 (0.63–1.19)        |         |
| Composite of all-cause mortality,       | Reference 0.82 (0.71–0.95)     | 0.010*                           | 0.78 (0.64–0.96)        | 0.020*  |
| myocardial infarction and stroke        | Reference                      |                                  | 0.95 (0.77–1.18)        |         |

*Significant P value(s) after using the Bonferroni-Holm method to control for multiple comparisons.
of MACE compared with group 1 (HR, 0.74; 95% CI, 0.63–0.86; \(P < 0.001\)), but patients in group 3 had similar risks of MACE compared with group 1 (HR, 0.73; 95% CI, 0.55–0.97; \(P = 0.027\)) and group 2 (HR, 0.99; 95% CI, 0.75–1.31, \(P = 0.95\)).

Next, we excluded 256 patients from group 2 because they achieved less than 50% reduction in LDL-C (if newly started on statin after PCI) or failed to reduce LDL-C below 70 mg/dL (1.8 mmol/L). The risks of MACE remained significantly lower in group 2 (HR, 0.82; 95% CI, 0.72–0.94, \(P = 0.003\)) and group 3 (HR, 0.75; 95% CI, 0.62–0.90; \(P = 0.002\)) when compared with group 1. The risks of MACE were similar between group 2 and group 3 (HR, 0.92; 95% CI, 0.76–1.11, \(P = 0.37\)). These findings were consistent with the primary analysis.

After propensity score matching, 5,110 patients (2,555 pairs) in group 1 and group 2 were matched. The baseline characteristics were well-balanced with standardized differences of <0.1 in all variables except age (Supplementary Table 1 in the Supplementary Appendix). The risk of MACE was lower in group 2 compared with group 1 (HR, 0.78; 95% CI, 0.68–0.90; \(P < 0.001\)) (Figure 3).

A total of five variables in the Cox regression model had missing data. Multiple imputation was conducted, and the imputed cohort included all 611(7.1%) patients who were excluded due to missing values in any of the variables used in the model. In the imputed dataset, the risks of MACE were significantly lower in group 2 (HR, 0.82; 95% CI, 0.72–0.93; \(P = 0.001\)) and group 3 (HR, 0.73; 95% CI, 0.62–0.88; \(P = 0.001\)) compared with group 1, but the risks of MACE were similar between group 2 and group 3 (HR, 1.22; 95% CI, 0.75–1.08, \(P = 0.26\)). These findings were consistent with the complete case cohort.

Exploratory Analyses
The benefits of high-intensity statin were consistent across all subgroups. There was no significant interaction between lipid management strategy and predefined subgroups on the primary outcome (Table 5 and Figure 4).

DISCUSSION
In this cohort of 8,650 adult patients who underwent a first-ever PCI, we showed that high-intensity statins, with or without attainment of LDL-C target in accordance to the latest guideline,
were associated with a lower adjusted risk of MACE and all-cause mortality at 5 yr, compared with patients who attained LDL-C target without high-intensity statins. Our data suggests that a strategy of routine high intensity statin may be more suited to the Asian population.

An extensive body of evidence from RCT has shown that statins can reduce cardiovascular events, with greater benefits derived from higher intensity statins (2, 3). All, except one RCT, either compared a fixed-dose statin with placebo (or no treatment) or compared statins at different intensities. The one exception was a RCT designed to evaluate the effect of dose-adjustment to achieve certain LDL-C target in patients with ischemic stroke, (16) but cardiac outcomes were not examined. The 2013 ACC/AHA guideline had recommended the use of high-intensity statins for all patients with atherosclerotic cardiovascular disease (ASCVD), and deemphasized targeting specific LDL-C levels (4). This was a significant departure from other societal guidelines, e.g., Adult Treatment Panel III Guidelines (17) and National Lipid Association Recommendations (18). Although the updated 2018 ACC/AHA guideline includes a goal of 50% reduction in LDL-C levels, routine high-intensity statins remain as the guiding principle of lipid management (5). In contrast, the 2019 ESC/EAS guideline takes a different approach and retains a goal approach to lipid management, recommending a LDL-C target of <55 mg/dl with a 50% reduction from baseline for patients with ASCVD (6). It interprets the totality of evidence as a reflection that cardiovascular risk reduction is proportional to the absolute

![Forest plot for subgroup analyses. The decreased risks of major adverse cardiovascular events in group 2 (intensity criteria only) compared with group 1 (target criteria only) were similar across all subgroups.](image-url)
reduction in LDL-C levels, and that benefits related to LDL-C reduction are not specific to statin therapy. Each of these two approaches has its own merits and short-comings. Routine high-intensity statins for secondary prevention is in line with the large body of evidence showing that the benefits of statin are similar across all levels of baseline LDL-C without any threshold (3). However, lack of emphasis on LDL-C target may make it difficult for clinicians to incorporate the newer effective, non-statin-lipid lowering therapies, (19–21) particularly as an add-on therapy in patients who can tolerate high-intensity statins (22–24).

To our best knowledge, there are no published data comparing these approaches at the most contemporary recommendations. One study used a previous LDL-C target (<70 mg/dL or >50% reduction from baseline level) and found that high-intensity statins were associated with a lower risk of MACE (14). Another study showed that on-treatment, LDL-C level was an independent predictor of MACE, but statin intensity was not (23). Our data suggested that Asians would benefit from high-intensity statins, regardless of attainment of LDL-C target. Importantly, we observed a reduction in mortality which is considered as the important outcome from a perspective of a patient.

There are several plausible explanations. First, the absolute reduction in LDL-C was greater in the high-intensity statin groups (group 2 and 3), and it is likely that the beneficial effects was mediated by LDL-C reduction. Large meta-analyses have concluded that each unit reduction in LDL-C was associated with similar relative risk reduction of MACE without any threshold level (3, 26). Collectively, the LDL-C hypothesis and “the lower the better” principle withstood the test of time (27). Second, statins have several beneficial lipid-independent (pleotropic) effects on atherosclerotic lesions, including favorable effects on endothelial function, modulation of inflammatory response, inhibition of coagulation cascade, and stabilization of plaques (28–31). Pathogenic investigations and clinical trials have suggested that these pleotropic effects of statins are dose-dependent (30, 32, 33). Third, triglyceride levels were lower with a greater degree of reduction in the high intensity statin groups, lending an alternative mechanism to decreasing cardiovascular risk (34).

Due to genetic polymorphism, the plasma levels of statin can be doubled in Asians as compared with Caucasians (7, 8). Asians typically achieve similar LDL-C reduction at lower statin doses (35, 36). Previous observational studies in various Asian populations did not demonstrate superior cardiovascular outcomes with high-intensity statins after PCI and acute myocardial infarction, (9–12) thereby resulting in vastly different statin-prescribing practices. In Japan, for instance, none of the statins is approved at high intensity doses (37). The majority of Asian societal guidelines still recommend a LDL-C target of 70–100 mg/dL for secondary prevention, substantially looser than the ESC/EAS guideline (38–40).

In future guideline revisions, emphasis should be made on either routine high-intensity statins or, if a target should be recommended for practical purposes, on absolute or percentage reduction of LDL-C, as opposed to a universal target for patients with ASCVD. From a practical perspective, 56.7% of the screened patients in our study, unfortunately, received care that was adherent to neither of the two major societal guidelines (Figure 1). This translational gap called for methods that can effectively increase guideline adherence. Further studies are needed to understand the effects of statin adherence, cholesterol variability, and applicability in primary prevention or other subgroups such as elderly or diabetics, (41–43) although we did not observe any effect modification in our subgroup analysis.

This study has some limitations. First, the observational nature of the study conferred risks of unmeasured confounding and bias. However, the large population-based sample size allowed extensive adjustment for potential confounders that may affect lipid management strategy and outcomes, and the findings were consistent with multiple sensitivity analyses. Our data was retrieved from a population-based electronic database with minimal loss to follow up and complete information on laboratory results and subsequent events. All information was recorded a priori, thus minimizing the selection, information, and recall biases. Second, we only included patients who had first-ever PCI and survived 365 days, and so the findings may not be applicable to those with recurrent coronary stenosis. We also could not evaluate the effects of high intensity statin initiated before PCI (44, 45). Third, this was an as-treated analysis, and there may be unexplored reasons behind the eventual lipid management strategy.

| Subgroup                           | Hazard Ratio (95% confidence interval) | P value for Interaction |
|------------------------------------|----------------------------------------|-------------------------|
| **Sex**                            |                                        |                         |
| Male                               | 0.83 (0.72–0.97)                       | 0.67                    |
| Female                             | 0.78 (0.59–1.03)                       |                         |
| **Age Group**                      |                                        |                         |
| Age<65                             | 0.91 (0.75–1.11)                       | 0.43                    |
| Age≥65                             | 0.77 (0.64–0.93)                       |                         |
| **Diabetes**                       |                                        |                         |
| No diabetes                        | 0.81 (0.68–0.97)                       | 0.50                    |
| With diabetes                      | 0.83 (0.68–1.01)                       |                         |
| **Baseline Renal Function**        |                                        |                         |
| eGFR<60ml/min/1.73m2               | 0.62 (0.70–0.96)                       | 0.59                    |
| eGFR<60ml/min/1.73m2               | 0.82 (0.65–1.04)                       |                         |
| **Indication for PCI**             |                                        |                         |
| Stable coronary artery disease     | 0.97 (0.72–1.31)                       | 0.24                    |
| Acute coronary syndrome            | 0.78 (0.67–0.91)                       |                         |

eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention.
lower adjusted risk of MACE at 5 yr, compared with patients who attained LDL-C target without high-intensity statins.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements. Written informed consent was not obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

AN and C-WS were responsible for the conception and design of the study. AN analyzed the data collected by AI. AN interpreted the data. AN and PN drafted the manuscript. All the authors revised and approved the final manuscript, and are accountable for the accuracy and integrity of the study.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.760926/full#supplementary-material

**REFERENCES**

1. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1 Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J.* (2017) 38:2459–72. doi: 10.1093/eurheartj/hxh144

2. Cholesterol Treatment Trials C, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet.* (2015) 385:1397–405. doi: 10.1016/S0140-6736(14)63684-4

3. Cholesterol Treatment Trials C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* (2010) 376:1670–81. doi: 10.1016/S0140-6736(10)61350-5

4. Stone NJ, Robinson JG, Lichtenstein AH, Bailey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation.* (2014) 129:51–45. doi: 10.1161/01.cir.0000437738.63853.7a

5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birnher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVP/APA/ARCH/ACPM/ADA/AGS/APHa/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *J Am Coll Cardiol.* (2019) 73:3168–209.

6. Macl F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidemia: lipid modification to reduce cardiovascular risk. *Eur Heart J.* (2020) 41:111–88. doi: 10.15289/1560-4071-2020-3826

7. Lee E, Ryan S, Birmingham B, Zaliwski J, March R, Ambrose H, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. *Clin Pharmacol Ther.* (2005) 78:330–41. doi: 10.1016/j.clpt.2005.06.013

8. Birmingham BK, Bujae SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. *Eur J Clin Pharmacol.* (2015) 71:329–40. doi: 10.1007/s00228-014-1800-0

9. Park MW, Park GM, Han S, Yang Y, Kim YG, Roh JH, et al. Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: a propensity-score matching analysis. *PLoS ONE.* (2018) 13:e0207889. doi: 10.1371/journal.pone.0207889

10. Natsuki M, Furukawa Y, Morimoto T, Nakagawa Y, Ono K, Kaburagi S, et al. Intensity of statin therapy, achieved low-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after coronary revascularization. Perspectives from the CREDO-Kyoto registry cohort-2. *Circ J.* (2012) 76:1369–79. doi: 10.1253/circj.CJ-11-1356

11. Yeh YT, Yin WH, Tseng WK, Lin FJ, Yeh HI, Chen JW, et al. Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: which matters in the real world? Statin intensity or low-density lipoprotein cholesterol level? Data from a multicenter registry cohort study in Taiwan. *PLoS ONE.* (2017) 12:e0186661. doi: 10.1371/journal.pone.0186661

12. Chen PS, Lin SH, Lee CH, Lin HW Li YH. Efficacy and safety of high-intensity statins in patients with acute myocardial infarction: an asian perspective. *Can J Cardiol.* (2020) 36:886–92. doi: 10.1016/j.cjca.2019.10.027

13. Sakamoto T, Ogawa H. “Just make it lower” is an alternative strategy of lipid-lowering therapy with statins in Japanese patients: LDL-cholesterol: the lower, the better; is it true for Asians? *Circ J.* (2010) 74:1731–41. doi: 10.1253/circj.CJ-10-0537

14. Kim J, Park KT, Jang MJ, Park TK, Lee JM, Yang H, et al. High-intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention. *J Am Heart Assoc.* (2018) 7:e009517. doi: 10.1161/JAHA.118.009517

15. Giacalone M, Agata Z, Cozcuoli PC, Alibrandi A, Bonferroni-Holm and permuation tests to compare health data: methodological and applicative issues. *BMCMed Res Methods.* (2018) 18:81. doi: 10.1186/s12874-018-0545-8

16. Amarencio P, Kim JS, Labreveche J, Charles H, Abtian J, Jeboit J, et al. A comparison of two LDL cholesterol targets after ischemic stroke. *N Engl J Med.* (2020) 382:9. doi: 10.1056/NEJMoa1910335

17. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation.* (2002) 106:3143–421. doi: 10.1161/01.cir.106.25.3143

18. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipoid association recommendations for patient-centered management of dyslipidemia: part 1–full report. *J Clin Lipidol.* (2015) 9:129–69. doi: 10.1016/j.jclnl.2015.02.003

19. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med.* (2015) 372:3238–97. doi: 10.1056/NEJMoa1410489

20. Sabatine MS, Giugliano RP, Keech AC, Hanoupour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med.* (2017) 376:1713–22. doi: 10.1056/NEJMoa1615664
21. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med.* (2018) 379:2097–107. doi: 10.1056/NEJMoA1801174
22. Shrank WH, Barlow JF, Brennan TA. New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines. *JAMA.* (2015) 314:1443–4. doi: 10.1001/jama.2015.10017
23. O’Keefe JH, DiNicolantonio JJ, Lavie CJ. Statins, ezetimibe, and proprotein convertase subtilisin–kexin type 9 inhibitors to reduce low-density lipoprotein cholesterol and cardiovascular events. *Am J Cardiol.* (2017) 119:565–71. doi: 10.1016/j.amjcard.2016.11.001
24. Ray KK, Kastelein JJ, Boekholdt SM, Nicholls SJ, Khaw KT, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. *Eur Heart J.* (2014) 35:960–8. doi: 10.1093/eurheartj/ehu107
25. Ross EG, Shah N, Leeper N. Statin Intensity or Achieved LDL? Practice-based evidence for the evaluation of new cholesterol treatment guidelines. *PLoS ONE.* (2016) 11:e0154952. doi: 10.1371/journal.pone.0154952
26. Bangalore S, Fayyad R, Kastelein JJ, Laskey R, Amarenco P, DeMicco DA, et al. 2013 Cholesterol guidelines revisited: percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? *Am J Med.* (2016) 129:584–91. doi: 10.1016/j.amjmed.2015.10.024
27. Jarcho JA, Keney JF. Proof that lower is better–LDL cholesterol and IMPROVE-IT. *N Engl J Med.* (2015) 372:2448–50. doi: 10.1056/NEJMe1507041
28. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. *J Am Coll Cardiol.* (2005) 46:1425–33. doi: 10.1016/j.jacc.2005.05.086
29. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. *JAMA.* (1998) 279:1643–50. doi: 10.1001/jama.279.20.1643
30. Oikonomou E, Siasos G, Zaromitidou M, Hatzis G, Mourouzis K, Chrysohoou C, et al. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. *Atherosclerosis.* (2015) 238:159–64. doi: 10.1016/j.athorosclerosis.2014.12.014
31. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. *Circulation.* (2004) 109:II39–43. doi: 10.1161/01.CIR.0000135157.2007.5a
32. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. *JAMA.* (2004) 291:1071–80. doi: 10.1001/jama.291.9.1071
33. Wiklund O, Mattsson-Hulten L, Hurt-Camejo E, Oscarsson J. Effects of simvastatin and atorvastatin on inflammation markers in plasma. *J Intern Med.* (2002) 251:338–47. doi: 10.1046/j.1365-2796.2002.00966.x
34. Marston NA, Giugliano RP, Ip K, Silverman MG, O’Donoghue ML, Wiviott SD, et al. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. *Circulation.* (2019) 140:1308–17. doi: 10.1161/CIRCULATIONAHA.119.041998
35. Liao JK. Safety and efficacy of statins in Asians. *Am J Cardiol.* (2007) 99:410–4. doi: 10.1016/j.amjcard.2006.08.051
36. Matsuzawa Y, Kita T, Mabuchi H, Matsuoka M, Nakaya N, Okawa S, et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. *Circ J.* (2003) 67:287–94. doi: 10.1253/circj.67.287
37. Saito M, Hirata-Koizumi M, Urano T, Miyake S, Hasegawa R. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. *J Clin Pharm Ther.* (2005) 30:21–37. doi: 10.1111/j.1365-2710.2004.00605.x
38. Li YH, Ueng KC, Jeng JS, Chang MJ, Lin TH, Chien KL, et al. 2017 Taiwan lipid guidelines for high risk patients. *J Formos Med Assoc.* (2017) 116:217–48. doi: 10.1016/j.jfma.2016.11.013
39. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. *J Atheroscler Thromb.* (2018) 25:846–984. doi: 10.5551/jat.JGL2017
40. Joint committee for guideline r. 2016 Chinese guidelines for the management of dyslipidemia in adults. *J Geriatr Cardiol.* (2018) 15:1–29. doi: 10.11099/issn.1671-5411.2018.01.011
41. Lavie G, Hoshen M, Leibowitz M, Benis A, Akirv A, Balicer R, et al. Statin therapy for primary prevention in the elderly and its association with new-onset diabetes, cardiovascular events, and all-cause mortality. *Am J Med.* (2021) 133:643–52. doi: 10.1016/j.amjmed.2020.09.058
42. Lee S, Zhou J, Wong WT, Liu T, Wu WKK, Wong ICK, et al. Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. *BMC Endocr Disord.* (2021) 21:94. doi: 10.1186/s12902-021-00751-4
43. Lee S, Zhou J, Guo CL, Wong WT, Liu T, Wong ICK, et al. Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death. *Endocrino Diabetes Metab.* (2021) 4:e00240. doi: 10.1002/edm2.240
44. Wang L, Peng P, Zhang O, Xu X, Yang S, Zhao Y, et al. High-dose statin pretreatment decreases peri-procedural myocardial infarction and cardiovascular events in patients undergoing elective percutaneous coronary intervention: a meta-analysis of twenty-four randomized controlled trials. *PLoS ONE.* (2014) 9:e113552. doi: 10.1371/journal.pone.0113352
45. Pan Y, Tan Y, Li B, Li X. Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials. *Lipids Health Dis.* (2015) 14:97. doi: 10.1186/s12944-015-0095-1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.